key: cord-0746618-fjl586sg authors: Pozzilli, Paolo; Lenzi, Andrea title: Testosterone, a key hormone in the context of COVID-19 pandemic date: 2020-04-27 journal: Metabolism DOI: 10.1016/j.metabol.2020.154252 sha: 88ee59a93a6f5d1e5dd23f54954607c552b8f7aa doc_id: 746618 cord_uid: fjl586sg nan J o u r n a l P r e -p r o o f Paolo Pozzilli MD (1) and Andrea Lenzi MD (2) ( Daily data show that entire population with SARS-CoV2 is 58% made of males [1] [2] [3] . The difference in the number of cases reported by gender increases progressively in favor of male subjects up to the age group ≥60-69 (66.6%) and ≥70-79 (66.1%), with the exception of the 20-29 years and 30-39 years group in which the number of female subjects it is slightly higher. Furthermore, higher lethality is in favor of male subjects The initial clinical manifestation of the COVID-19 is pneumonia, though are described gastrointestinal symptoms and asymptomatic infections, the last not yet been definitely assessed 5 . The infection can progress to severe disease with dyspnoea and chest symptoms corresponding to pneumonia in the second or third week of a symptomatic infection. Clinical data show decreased oxygen saturation, changes visible through chest X-rays and other imaging techniques. Furthermore, lymphopenia appears to be common, and an increase of inflammatory markers (C-reactive protein and pro-inflammatory cytokines) has been reported 6 . It is well established that plasma testosterone concentration is reduced by age and comorbidities like obesity, diabetes and obstructive sleep apnea (OSA) 7 , all comorbidities highly prevalent in COVID-19 patients 8 Several studies have shown that in men with chronic obstructive pulmonary disease (COPD) hypogonadism is associated with a prevalence ranging between 22% and 69% 9 . In this context low testosterone levels can cause a reduction of respiratory muscles activity and overall strength and exercise capacity 10 , whilst normal circulating testosterone levels show a protective effect on several respiratory outcomes (i.e. forced expiratory volume in one second-FEV1, and forced vital capacity -FVC) 11 . A randomized controlled trial reported an improvement in peak oxygen consumption in men receiving testosterone replacement therapy 12 . SARS-CoV2 infects lung alveolar epithelial cells using as an entry receptor the angiotensin-converting enzyme II (ACE2) 13 . ACE2 plays a role in lung protection and therefore viral binding to this receptor may deregulate a lung protective pathway 14 . Interestingly, studies showed that ACE2 is a constitutive product of adult-type Leydig cells 15 , thus implying a role in testicular function and suggesting a possible involvement of testicle in COVID-19 infected patients, a factor which may affect testosterone secretion. Pro-inflammatory cytokines have a central role in the progression of COVID-19 infection. Reduction of cytokine activity and/or their receptors (anti-cytokine therapy), can be useful for treatment. In this context testosterone may downregulate inflammation. As a matter of fact, several studies carried out both in animals and humans showed that hypogonadism is associated with increased pro-inflammatory cytokines and that testosterone treatment reduces IL-1β, IL-6, and TNF-α 16 . Furthermore, the association between an increase J o u r n a l P r e -p r o o f of pro-inflammatory state and decline in testosterone is often observed in aging men 17 and in men with stable coronary artery disease 18 . Based on the above considerations, the hypothesis arises that testosterone may have a role in the cascade of events leading to progression of COVID-19 infection due to the cytokine storm. Suppression of ACE2 expression by inflammatory cytokines accompanied by the decrease of androgens and estrogens of the elderly, may establish a negative correlation between ACE2 expression and COVID-19 mortality 19 . Measuring testosterone levels may be recommended at the time of an identified COVID-19 positive patient. At present data on testosterone can be collected systematically at one or more institutions. If values are low, use of testosterone may be considered to reduce the associated pulmonary syndrome, thus preventing progression to severe COVID-19 disease where pro-inflammatory cytokines play a major role. In a further selection of patients for testosterone treatment, avoidance of enrolling patients in whom therapy with the hormone is contraindicated, should be taken into account. A proper randomized trial with testosterone should be then designed. As opposed to what mentioned earlier, stands the testosterone-driven COVID-19 theory 20 . This is based on the androgen receptor activation of the transcription of a transmembrane protease, serine 2 (TMPRSS2), exploring possible implications in risk stratification and transmissibility of COVID-19 infection 21 . Although other proteases were described to activate the COVID-19 spikes in vitro, only TMPRSS2 activity is regarded as essential for viral spread and pathogenesis in the infected hosts 22 . TMPRSS2 may also cleave ACE2 for augmented viral entry 23 . Androgen receptor activity has been considered a requirement for the transcription of TMPRSS2 gene as no other known TMPRSS2 gene promoter has been reported to exert the same action in humans 24, 25 . The modulation of TMPRSS2 expression by testosterone has been suggested to contribute to male predominance of COVID-19 infection 26 . Finally, TMPRSS2 is both the most frequently altered gene in primary prostate cancer and a critical factor enabling cellular infection by SARS-CoV-2 24 . The hyper adrogenic phenotype could explain the COVID-19 positivity in those few young males with severe COVID-19 infection 27 , possibly with shorter AR CAG lengths, who are at greater risk of developing prostate cancer because higher receptor transcription activity 28 . A role for TMPRSS2 variants and its expression levels in modulating COVID-19 severity has been suggested, leading to foster a rapid experimental validation on large cohorts of patients with different clinical manifestations of COVID-19 infection 29 . Since TMPRSS2 are expressed also at pulmonary level, the use of TMPRSS2 inhibitors, currently used for prostate cancer, represent an appealing target for prevention or treatment of COVID-19 pneumonia 21, 22 . Studies are required to validate this hypothesis and to evaluate the therapeutic and prophylactic potential of drugs that temporarily target androgen activity, such as androgen receptor inhibitors, steroidogenesis inhibitors and 5-alpha reductase inhibitors 20 . The elucidation of the role of testosterone in the battle towards COVID-19 infection turns out to be an urgent need. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) -China, 2020. China CDC Wkly Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis Sex-and Gender-specific Observations and Implications for COVID-19 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster The COVID-19 epidemic Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease Hypogonadism in chronic obstructive pulmonary disease: Incidence and effects Androgens are bronchoactive drugs that act by relaxing airway smooth muscle and preventing bronchospasm Higher serum testosterone and dihydrotestosterone, but not oestradiol, are independently associated with favourable indices of lung function in communitydwelling men Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure. A Double-Blind, Placebo-Controlled, Randomized Study ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19 Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19 The novel Angiotensin-Converting Enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis The relationship between circulating testosterone and inflammatory cytokines in men The relationship between testosterone and molecular markers of inflammation in older men Inverse relationship between serum levels of interleukin-1βand testosterone in men with stable coronary artery disease Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation SARS-COV-2 infection is likely to be androgen mediated SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis National Institutes of Health. TMPRSS2 transmembrane serine protease 2 TMPRSS2 and COVID-19 : Serendipity or Opportunity for Intervention ? Cancer Discov Clinical Characteristics of Coronavirus Disease 2019 in China Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Prepr from medRxiv bioRxiv. 2020:1-20. Prepr -not peer J o u r n a l P r e -p r o o f Funding: none